Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
13 August 2024 | Story André Damons | Photo Supplied
Maricel-van-Rooyen
Maricél van Rooyen, Project Manager for Research Information Management System (RIMS) and Research Ethics Adviser in the Directorate Research Development (DRD) at the University of the Free State (UFS), is the Programme Coordinator for a first-of-its-kind Southern African Research and Innovation Management Association (SARIMA)/ COP webinar on Environment and Biosafety Research Ethics.

The University of the Free State (UFS) is playing host to a first-of-its-kind webinar on Environment and Biosafety Research Ethics later this month with Maricél van Rooyen, Project Manager for Research Information Management System (RIMS) and Research Ethics Adviser in the Directorate Research Development (DRD), playing a pivotal role.

The webinar, which is part of the Eastern Region Community of Practice (COP), is taking place on 20 August. The target market for this virtual workshop is Biosafety and Environmental Research Ethics Committee (REC) chairpersons and members, professionals including research management professionals, administrators, research compliance managers and advisers, and research directors in Southern Africa and beyond.

Van Rooyen will be the Programme Coordinator for this Southern African Research and Innovation Management Association (SARIMA)/ COP Research Ethics Webinar, while Prof Robert Bragg, chairperson of the UFS Environmental and Biological Research Ethics Committee (EBREC), will give a presentation on the establishment of an EBREC.

The UFS, Stellenbosch University and the University of the Witwatersrand, form part of the COP which is a SARIMA (Southern African Research and Innovation Management Association) initiative to assist and share research ethics questions between institutions to empower research management and ethics compliance. SARIMA assisted with the online hosting and advertising of the webinar.

Purpose of the webinar

“Environment and Biosafety Committees in South Africa are a new idea, and only a few institutions in the country have such a committee. The UFS and the other institutions that will present at the workshop, take a leading role because they have already registered committees in place. We want to share and assist with establishing and operating such committees,” says Van Rooyen.

According to her, the need for the webinar arises from the upsurge of research and innovation in biotechnology and related fields over the past two decades that has led to exciting new discoveries in areas such as the engineering of biological processes, gene editing, stem cell research, CRISPR-Cas9 technology, Synthetic Biology, recombinant DNA, LMOs and GMOs, to mention only a few.

These advances, however, have generated concerns about biosafety, biosecurity and adverse impacts on biodiversity and the environment, leading to the establishment of Research Ethics Committees (RECs) at Higher Education and Research Institutions dedicated to reviewing research with implications for biosafety and the environment.

These EBRECs are in the early stages of their establishment and formalisation in South Africa, and there is much uncertainty about their composition, scope, procedures of decision-making and the principles that should guide their deliberations and assessments.

Leading the charge

The UFS took the lead in South Africa in ensuring international ethical compliance in this extended area of research, by establishing its own Environmental and Biological Research Ethics Committee (EBREC) six years ago. The UFS EBREC is one of only two such ethics committees at a South African university that combines the biosafety committee with environmental and biological research ethics to ensure ethics compliance in these fields.  The initiative started with Van Rooyen and her RIMS EthicsTeam, (Willem Kilian and Amanda Smith). The university is again taking charge with this webinar, which is a first of its kind.  

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept